Vorinostat also known as suberoylanilide hydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA), is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of biological effects, including modulation of chromatin structure, altered transcriptional programs, changes in DNA repair pathways, and effects on nonhistone protein acetylation; Vorinostat contains a hydroxamic acid zinc binding motif that coordinates the catalytic zinc ion in Class I and II HDAC active sites, producing increased acetylation of histone H3 and H4, induction of CDK inhibitors such as p21, cell cycle arrest, and apoptosis in susceptible tumor cells. Chemically, Vorinostat is a small molecule with reasonable aqueous solubility for oral capsule formulation, is absorbed after oral dosing with peak plasma concentrations within a few hours, is metabolized mainly by glucuronidation and beta-oxidation pathways, and is eliminated primarily in the urine; common clinical doseing is 400 mg once daily for approved indications, dose modifications are required for specific toxicities, and key safety monitoring includes hematologic parameters, liver function tests, and electrocardiographic assessment when clinically indicated.
Typical analytical and quality control expectations for Vorinostat active pharmaceutical ingredient include a validated assay target typically near 98.0 to 102.0 percent by HPLC, water content generally kept at or below 2.0 percent w w, and control of related substances and process impurities consistent with ICH Q3A and Q3B principles; a representative specification framework would allow individual identified related compounds at or below 0.5 percent w w each, total related impurities not to exceed 2.0 percent w w, unspecified impurities reporting threshold about 0.1 percent w w, residual solvents controlled per ICH Q3C with class specific limits (for example methanol up to 3000 ppm, DMF up to 880 ppm when applicable), heavy metals below typical pharmacopoeial limits such as 20 ppm, and limits for specific known process- and degradation-related species such as hydrolysis products, anilide-related homologs, and N-oxidation products established by structure elucidation and toxicological risk assessment; actual finished product impurity limits and acceptance criteria should follow the approved regulatory dossier or pharmacopeial monograph.
Vorinostat is approved for treatment of cutaneous T cell lymphoma in patients with progressive, persistent or recurrent disease after prior systemic therapy; it is also studied and sometimes used off-label in other hematologic and solid tumor indications under clinical supervision.
Yes, Vorinostat is a histone deacetylase inhibitor that binds the catalytic zinc ion in HDAC enzymes, inhibiting Class I and II HDAC activity and increasing acetylation of histone and nonhistone proteins.
Cost varies by country, formulation, brand versus generic availability, insurance coverage, and dispensing pharmacy; branded product list prices can be high and out of pocket costs without insurance may range from several thousand to much higher per month, while generic versions and assistance programs can substantially reduce patient cost; check current pharmacy pricing or payer formularies for an exact figure.
Yes, Vorinostat received FDA approval for the treatment of cutaneous T cell lymphoma in patients with progressive, persistent or recurrent disease after prior systemic therapy.
